SCHEMBL4787570

SCHEMBL4787570

O=Cc1ccc(OCC(=O)N2CCN(c3c(F)cccc3-c3cc(CNc4ccon4)on3)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ENPP2 Q13822 1/20 0.36
LMNA P02545 3/20 0.35
MAPK1 P28482 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 3/20 0.34
NFE2L2 Q16236 2/20 0.34
HTT P42858 2/20 0.33
PPARG P37231 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
USP2 O75604 1/20 0.33
TSHR P16473 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686057 0.90 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2KMT2AMEN1ENPP2
SCHEMBL4683309 0.89 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KMT2AMEN1ENPP2
SCHEMBL4684416 0.89 ENPP2 (0.46) KMT2AENPP2MAPK1KDM4EMAPT
SCHEMBL4678388 0.87 KDM4E (0.36) ALDH1A1SMN1; SMN2ENPP2MAPK1KDM4E
SCHEMBL4742831 0.86 NPC1 (0.38) SMN1; SMN2LMNAMAPTPOLB
SCHEMBL6400646 0.86 KDM4E (0.35) ALDH1A1SMN1; SMN2KMT2AMEN1MAPK1
SCHEMBL4686096 0.83 POLB (0.38) ALDH1A1LMNAMAPTTSHRPOLB
SCHEMBL4787561 0.81 ALDH1A1 (0.34) ALDH1A1KMT2AMEN1ENPP2
SCHEMBL4684196 0.78 BDKRB1 (0.34) KMT2AMEN1ENPP2MAPT
SCHEMBL4784687 0.77 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 ALDH1A1 1181/4885SMN1; SMN2 3326/4885KMT2A 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.